AB0759 BIOLOGICS IMPROVES ARTERIAL STIFFNESS WITH CS DMARDS-RESISTANT ACTIVE PSORIATIC ARTHRITIS. A COHORT STUDY

Background: Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascular prevention in PSA1). But there is no evidence of CV risk management and arterial stiffness about biologics in patients with PsA Objectives: To examine the effect of biologics plus conventional synthetic (cs) DMARDs on arterial stiffness in cs DMARDs resistant PsA patients in a cohort study design. Methods: 38 PSA and patients with moderate to severe active disease despite cs DMARDs treatment (disease activity score: DAPSA2) score>14) were received Biologics plus cs DMARDs. All patients have no previous history of CV. Arterial stiffness was assessed with cardio-ankle vascular index (CAVI, modified pulse wave velocity(PWV)) and augmentation index corrected for a heart rate of 75 beats per minute (AIx@75) at baseline and 24 weeks follow-up. Clinical data were collected at regular visits. CAVI is very similar to pulse wave velocity (PWV), and CAVI measures arterial wall stiffness independent of blood pressure and it is superior to brachial ankle PWV as an index of arterial stiffness2. Results: 35 PsA patients(18 patients adalimumab,13 patients infliximab, and 4 patients ustekinumab, respectively) completed this study, Treatment with biologics(10.88 ± 1.86 and 9.46± 1.14%; p = 0.006), attenuated the CAVI significantly from baseline to 24 weeks follow up. Treatment with biologics(36.4 ± 8.6, 32.1 ± 3.8%; p = 0.008) attenuated the aix@75 significantly from baseline to 24 weeks follow up. DAPSA score improved significantly from baseline to 24 weeks(17.45±6.33, 5.44±3.43: p=0.01). There are no significant differences among biologics about CAVI and aix@75. Surprisingly, improvement of CAVI and aIx@75 were not correlated disease activity at 24 weeks of biologics treatment (CAVI: p=0.91, aIx@75: p=0.88). Biologics improves arterial stiffness independently of its effects on disease activity, since even in high disease activity (4 cases; DAPSA score>28) is halted. Conclusion: These findings suggest that combination therapy, biologics with cs DMARDs not only reduced PsA disease activity but also limited vascular damage in patients with cs DMARDS resistant active PsA References [1] Soren Lund Kristensen, et al. Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation?Ann Rheum Dis. 2015; 74: 321-2. [2] Schoels MM, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis, 2016; 75: 811-8. Acknowledgement: Thank you for all paitents and colleagues. Disclosure of interests: None declared